The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
986
October 25, 1996
View Complete Issue         Table of Contents 2019 
Topotecan Hydrochloride for Metastatic Ovarian Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Topotecan Hydrochloride for Metastatic Ovarian Cancer
October 25, 1996 (Issue: 986)
Topotecan hydrochloride (Hycamtin - SmithKline Beecham) was recently approved by the U.S. Food and Drug Administration for parenteral use as a single agent in patients with metastatic ovarian cancer refractory to other drugs. Initial treatment for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Topotecan Hydrochloride for Metastatic Ovarian Cancer
Article code: 986b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.